Group structure
9 companies in 5 countries
Loading…
9 companies in 5 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 81
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AUGTYRO160mg | 40mg · Capsule | Repotrectinib | United States | Marketed | 2023 |
| BETAPEN-VK250mg base | 500mg base · Tablet | Phenoxymethylpenicillin | United States | Not marketed | |
| BRISTACYCLINE250mg | 500mg · Capsule | Tetracycline | United States | Not marketed | 1972 |
| BRISTAGEN40mg base/ml · Injectable | Gentamicin | United States | Not marketed | |
| BRISTAMYCIN250mg base · Tablet | Erythromycin | United States | Not marketed | 1974 |
| CAMZYOS10mg | 15mg | 2.5mg | 5mg · Capsule | Mavacamten | United States | Marketed | 2022 |
| ELIQUIS0.15mg · Suspension | Apixaban | United States | Marketed | 2025 |
| ELIQUIS SPRINKLE0.15mg · For suspension | Apixaban | United States | Marketed | 2025 |
| EVOTAZ300mg base; 150mg · Tablet | Atazanavir, Cobicistat | United States | Marketed | 2015 |
| KRAZATI200mg · Tablet | Adagrasib | United States | Marketed | 2022 |
| MEXATE100mg base/vial | 20mg base/vial | 250mg base/vial | 50mg base/vial · Injectable | Methotrexate | United States | Not marketed | 1979 |
| ONUREG200mg | 300mg · Tablet | Azacitidine | United States | Marketed | 2020 |
| POLYCILLIN250mg base | 500mg base · Capsule | Ampicillin | United States | Not marketed | |
| POLYCILLIN100mg base/ml | 125mg base/5ml | 250mg base/5ml | 500mg base/5ml · For suspension | Ampicillin | United States | Not marketed | |
| POLYCILLIN125mg base · Tablet, chewable | Ampicillin | United States | Not marketed | |
| POLYCILLIN-N125MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reason · Injectable | Ampicillin | United States | Not marketed | |
| POLYCILLIN-PRB3.5gm base/bot; 1gm/bot · For suspension | Ampicillin, Probenecid | United States | Not marketed | 1974 |
| POMALYST1mg | 2mg | 3mg | 4mg · Capsule | Pomalidomide | United States | Marketed | 2013 |
| PRECEF10gm/vial | 1gm/vial | 20gm/vial | 2gm/vial | 500mg/vial · Injectable | Ceforanide | United States | Not marketed | 1984 |
| SOTYKTU6MG · Tablet | Deucravacitinib | United States | Marketed | 2022 |
| TETREX100mg hydrochloride | 250mg hydrochloride | 500mg hydrochloride · Capsule | Tetracycline complex | United States | Not marketed | 1957 |
| ULTRACEF500mg base · Capsule | Cefadroxil | United States | Not marketed | |
| ULTRACEF125mg base/5ml | 250mg base/5ml | 500mg base/5ml · For suspension | Cefadroxil | United States | Not marketed | |
| VERSAPEN112.5mg ampicil/5ml | 112.5mg ampicil/ml | 225mg ampicil/5ml · For suspension | Hetacillin | United States | Not marketed | |
| VERSAPEN-K225mg ampicil | 450mg ampicil · Capsule | Hetacillin | United States | Not marketed | 1971 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 35 | 0 | 35 | CompaniesAll medicines |
| United States | 29 | 29 | 0 | CompaniesAll medicines |
| Romania | 14 | 0 | 14 | CompaniesAll medicines |
| Saudi Arabia | 3 | 3 | 0 | CompaniesAll medicines |
Also in the registers of Italy, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licence: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Keep Bristol’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callSaudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Well-known pharmaceutical groups, each with all its companies.